Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy

Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business